Press coverage about Corium International (NASDAQ:CORI) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corium International earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1240662238936 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
Several analysts have issued reports on the company. Zacks Investment Research downgraded Corium International from a “hold” rating to a “sell” rating in a report on Friday, December 29th. BidaskClub upgraded Corium International from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Needham & Company LLC boosted their price objective on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, November 20th. Finally, HC Wainwright set a $14.00 price objective on Corium International and gave the stock a “buy” rating in a report on Friday, February 9th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $12.86.
Corium International stock opened at $11.56 on Monday. The firm has a market capitalization of $417.59, a PE ratio of -7.32 and a beta of 1.50. Corium International has a twelve month low of $3.50 and a twelve month high of $13.93. The company has a quick ratio of 1.34, a current ratio of 1.40 and a debt-to-equity ratio of 5.91.
Corium International (NASDAQ:CORI) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $7.48 million. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. sell-side analysts forecast that Corium International will post -1.47 earnings per share for the current fiscal year.
In other Corium International news, major shareholder Life Sciences Maste Perceptive bought 510,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The shares were bought at an average price of $12.54 per share, for a total transaction of $6,395,400.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Perceptive Advisors Llc bought 50,350 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was acquired at an average price of $11.83 per share, for a total transaction of $595,640.50. The disclosure for this purchase can be found here. 30.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Corium International (CORI) Getting Somewhat Positive News Coverage, Study Finds” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/19/corium-international-cori-getting-somewhat-positive-news-coverage-study-finds.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.